Table 2.

Findings by microvascular invasion.

Characteristics	Microvascular invasion	p-value
Median number of affected segments	2.0 vs. 1.0	0.01∗
Median number of HCCs	1.0 vs. 1.0	0.23
Median HCC tumor size	3.5 vs. 2.5	0.09
Median AFP	18.8 vs. 8.8	0.02∗
HCC etiology, %
HCV	22.0 vs. 26.3	0.60
HBV	60.0 vs. 21.7	0.08
Alcohol	13.3 vs. 24.8	0.52
NAFLD	36.4 vs. 22.0	0.28
Segment
Segment 1	0.0 vs. 23.5	1.00
Segment 2	35.3 vs. 21.4	0.22
Segment 3	26.3 vs. 22.8	0.77
Segment 4a	36.8 vs. 20.8	0.14
Segment 4b	35.7 vs. 21.7	0.31
Segment 5	34.5 vs. 19.8	0.10
Segment 6	25.6 vs. 22.2	0.68
Segment 7	23.8 vs. 23.1	0.93
Segment 8	25.6 vs. 22.1	0.66
Segment 2 and 3	71.4 vs. 20.4	0.01∗
Segment 4a and b	34.6 vs. 20.2	0.12
Segment 5 and 6	26.9 vs. 20.6	0.42
Segment 6 and 7	24.2 vs. 22.4	0.82
Segment 7 and 8	24.2 vs. 22.2	0.79
Segment 4b and 5	37.5 vs. 16.3	0.01∗
Segment 4a and 8	27.3 vs. 20.0	0.35
Segment 4b and 8	29.1 vs. 18.5	0.17
Segment 5 and 8	42.9 vs. 20.8	0.09
BCLC A, B, and C stages	18.5 vs. 36.0 vs. 66.7	0.04∗
HCC pathology stage, 1, 2, and 3	12.4 vs. 51.6 vs. 50.0	≤0.01∗∗
HCC recurrence	78.6 vs. 14.0	≤0.01∗∗
Median survival, months	50 vs. 137	0.01∗

HCC: hepatocellular carcinoma, AFP: alpha fetoprotein, HCV: hepatitis C virus, HBV: hepatitis B virus, NAFLD: Nonalcoholic fatty liver disease, BCLC: Barcelona Clinic Liver Cancer, ^∗p < 0.05, ^∗∗p < 0.01.